Dosage & AdministrationDrug labelPrior authorizationPharmacyPatient educationPeople also ask
Spevigo(spesolimab-sbzo)
Spevigo 150 MG in 1 ML Prefilled Syringe
NO BOXED WARNING

Dosage & Administration

Dosage & Administration

Subcutaneous Dosage for Treatment of GPP When Not Experiencing a Flare

Administer a subcutaneous loading dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) subcutaneously 4 weeks later and every 4 weeks thereafter.

Intravenous Dosage for Treatment of GPP Flare


drug label

Spevigo Prescribing Information

Report Adverse Event

prior authorization

Spevigo Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form
Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form
Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form
Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form
Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form
Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form
Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form
Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form
Coverage Authorization Appeals: SC Spevigo
Letter of Medical Necessity: SC Spevigo
Letter of Medical Exception

Benefits investigation

BI Solution Plus Enrollment Form

pharmacy

Spevigo Preferred Pharmacy

Pharmacy List

patient education

Spevigo Patient Education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Spevigo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

people also ask

Spevigo FAQs

What is the risk of using SPEVIGO during pregnancy?The limited data on the use of SPEVIGO in pregnant women are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. However, human IgG is known to cross the placental barrier, so SPEVIGO may be transmitted from the mother to the developing fetus. In an animal reproduction study, intravenous administration of a surrogate antibody against IL36R in mice during the period of organogenesis did not elicit any reproductive toxicity.
What is the estimated background risk of birth defects and miscarriage for the indicated population?The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is SPEVIGO safe to use during lactation?There are no data on the presence of spesolimab-sbzo in human milk, the effects on the breastfed infant, or the effects on milk production. However, spesolimab-sbzo is a monoclonal antibody and is expected to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SPEVIGO and any potential adverse effects on the breastfed infant from SPEVIGO or from the underlying maternal condition.
Is SPEVIGO safe to use in pediatric patients?The safety and effectiveness of SPEVIGO in pediatric patients have not been established.
Is there a difference in safety profile between elderly and younger patients using SPEVIGO?Clinical studies of SPEVIGO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.
FAQ Data Source